Repurposing of Cetuximab in antibody-directed chemotherapy-loaded nanoparticles in EGFR therapy-resistant pancreatic tumours.

The anti-Epidermal Growth Factor Receptor (EGFR) antibody Cetuximab (CTX) has demonstrated limited anti-cancer efficacy in cells overexpressing EGFR due to activating mutations in RAS in solid tumours, such as pancreatic cancer. The utilisation of antibodies as targeting components of antibody-drug conjugates, such as trastuzumab emtansine (Kadcyla), demonstrates that antibodies may be repurposed to direct therapeutic agents to antibody-resistant cancers. Here we investigated the use of CTX as a targeting agent for camptothecin (CPT)-loaded polymeric nanoparticles (NPs) directed against KRAS mutant CTX-resistant cancer cells. CPT was encapsulated within poly(lactic-co-glycolic acid) (PLGA) NPs using the solvent evaporation method. CTX conjugation improved NP binding and delivery of CPT to CTX-resistant cancer cell lines. CTX successfully targeted CPT-loaded NPs to mutant KRAS PANC-1 tumours in vivo and reduced tumour growth. This study highlights that CTX can be repurposed as a targeting agent against CTX-resistant cancers and that antibody repositioning may be applicable to other antibodies restricted by resistance.

[1]  C. Scott,et al.  Antibody conjugated nanoparticles as a novel form of antibody drug conjugate chemotherapy. , 2018, Drug discovery today. Technologies.

[2]  Channing J Der,et al.  KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. , 2018, Cold Spring Harbor perspectives in medicine.

[3]  Yanping Zhang,et al.  SALL1 functions as a tumor suppressor in breast cancer by regulating cancer cell senescence and metastasis through the NuRD complex , 2018, Molecular Cancer.

[4]  S. Vicent,et al.  KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target , 2018, Molecular Cancer.

[5]  C. G. Mohan,et al.  In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts , 2017, International journal of nanomedicine.

[6]  Y-S Kim,et al.  Co-targeting of EGF receptor and neuropilin-1 overcomes cetuximab resistance in pancreatic ductal adenocarcinoma with integrin β1-driven Src-Akt bypass signaling , 2017, Oncogene.

[7]  Suguru Hasegawa,et al.  Metabolic Alterations Caused by KRAS Mutations in Colorectal Cancer Contribute to Cell Adaptation to Glutamine Depletion by Upregulation of Asparagine Synthetase12 , 2016, Neoplasia.

[8]  W. Scheithauer,et al.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. , 2016, The Lancet. Oncology.

[9]  M. Saif,et al.  The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy , 2016, Expert review of anticancer therapy.

[10]  Maria Filomena Botelho,et al.  MIA PaCa-2 and PANC-1 – pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors , 2016, Scientific Reports.

[11]  G. Chakrabarti.  Mutant KRAS associated malic enzyme 1 expression is a predictive marker for radiation therapy response in non-small cell lung cancer , 2015, Radiation oncology.

[12]  A. Anel,et al.  Liposome-bound TRAIL induces superior DR5 clustering and enhanced DISC recruitment in histiocytic lymphoma U937 cells. , 2015, Leukemia research.

[13]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[14]  D. Keskin,et al.  Epidermal growth factor receptor-targeted immunoliposomes for delivery of celecoxib to cancer cells. , 2015, International journal of pharmaceutics.

[15]  Yu Zhang,et al.  Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles , 2014, Scientific Reports.

[16]  David S. Jones,et al.  Efficient drug delivery and induction of apoptosis in colorectal tumors using a death receptor 5-targeted nanomedicine. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  Cai Qi,et al.  CORRIGENDUM: Analysis of interactions between SNARE proteins using imaging ellipsometer coupled with microfluidic array , 2014, Scientific Reports.

[18]  P. Johnston,et al.  Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity , 2014, Cell Death and Disease.

[19]  R. Lothe,et al.  Epigenetic and genetic features of 24 colon cancer cell lines , 2013, Oncogenesis.

[20]  L. Galluzzi,et al.  Novel multifunctional antibody approved for the treatment of breast cancer , 2013, Oncoimmunology.

[21]  Yun Yen,et al.  First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies , 2013, Investigational New Drugs.

[22]  B. C. Wong,et al.  Treatment of functional dyspepsia with sertraline: a double-blind randomized placebo-controlled pilot study. , 2012, World journal of gastroenterology.

[23]  Xiang Du,et al.  KRAS mutation testing in metastatic colorectal cancer. , 2012, World journal of gastroenterology.

[24]  E. Winer,et al.  A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[26]  S. Nair,et al.  In vitro targeted imaging and delivery of camptothecin using cetuximab-conjugated multifunctional PLGA-ZnS nanoparticles. , 2012, Nanomedicine.

[27]  D. Wheeler,et al.  Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab , 2011, Cancer biology & therapy.

[28]  F. Fay,et al.  Antibody-targeted nanoparticles for cancer therapy. , 2011, Immunotherapy.

[29]  J. Reichert.  Antibody-based therapeutics to watch in 2011 , 2011, mAbs.

[30]  P. V. van Diest,et al.  Oncogenic KRAS desensitizes colorectal tumor cells to epidermal growth factor receptor inhibition and activation. , 2010, Neoplasia.

[31]  J. Shea,et al.  Phenotype and Genotype of Pancreatic Cancer Cell Lines , 2010, Pancreas.

[32]  Patricia Greninger,et al.  A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. , 2009, Cancer cell.

[33]  L. Mazzucchelli,et al.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  P. McCarron,et al.  Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells. , 2008, Bioconjugate chemistry.

[35]  D. Mukhopadhyay,et al.  Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. , 2008, Cancer research.

[36]  Y. Pommier.  Topoisomerase I inhibitors: camptothecins and beyond , 2006, Nature Reviews Cancer.

[37]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[38]  N. Normanno,et al.  Epidermal growth factor receptor (EGFR) signaling in cancer. , 2006, Gene.

[39]  P. Jeffrey,et al.  Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. , 2005, Cancer cell.

[40]  L. Saltz,et al.  The camptothecins , 2003, The Lancet.

[41]  K. Bland,et al.  Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody. , 2003, The Journal of surgical research.

[42]  C. V. Pesheck,et al.  Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[43]  S. Shirasawa,et al.  Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. , 1993, Science.

[44]  J. Mendelsohn,et al.  Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. , 1984, Cancer research.